The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS).
Klaus Pietzner
No relevant relationships to disclose
Ignace Vergote
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
Frederik Marme
No relevant relationships to disclose
Per Rosenberg
No relevant relationships to disclose
Hilke Friccius-Quecke
Employment or Leadership Position - Fresenius Biotech
Jalid Sehouli
No relevant relationships to disclose